Aims To evaluate clinical profiles and outcomes in patients with systolic heart failure (HF)
with or without diabetes, and the efficacy and safety of ivabradine (heart rate‐lowering …

Background Readmission or death after heart failure (HF) hospitalization is a consequential
and closely scrutinized outcome, but risk factors may vary by population. We characterized …

Ivabradine is approved to reduce hospitalizations for patients with symptomatic heart failure,
reduced ejection fraction, and persistently elevated heart rate despite otherwise maximal …

Background: The sinus node inhibitor ivabradine was approved for patients with heart failure
(HF) after the ivabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure …

Objectives To analyse the effect of the early coadministration of ivabradine and beta-
blockers (intervention group) versus beta-blockers alone (control group) in patients …

Background In the Systolic Heart failure treatment with the I f inhibitor Trial (SHIFT)
randomised placebo-controlled trial, ivabradine was shown to reduce hospital admissions …

Aims Ivabradine has been approved in heart failure with reduced ejection fraction (HFrEF)
and elevated heart rate despite guideline‐directed medical therapy (GDMT) to reduce …

A high resting heart rate (≥ 70–75 bpm) is a risk factor for patients with heart failure (HF)
with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis …

Aims We explored the impact of being hospitalized due to worsening heart failure (WHF) or
a myocardial infarction (MI) on subsequent mortality in a large contemporary data set of …

Aims LIVE: LIFE is a multi-centre, open-label, prospective observational cohort study
assessing health-related quality of life (HRQoL) in older patients with chronic heart failure …